QuidelOrtho Corp — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 72/100
What the filing says
QuidelOrtho reported Q2 2026 revenue of $631M (3% growth; 2% constant currency), with Labs at $383M (+4%), Immunohematology at $134M (+1%), and Point of Care at $108M (+16%). However, the company cut full-year 2026 revenue guidance from $2.70–$2.75B to $2.52–$2.60B (−6.6% to −8.1%), adjusted EBITDA from $615–$630M to $540–$560M (−11.8% to −12.2%), and adjusted diluted EPS from $1.80–$2.00 to $0.65–$0.90 (−63.9% to −64.0%), citing China IVD pricing reductions and a softer respiratory environment. The company withdrew free cash flow guidance; China revenue fell 18.7% YoY in Q2.
Why this rating
Guidance cuts of 6–13% across revenue and earnings metrics represent ~$150–200M+ revenue and ~$75–90M EBITDA downside, material to a $1.9B market-cap company. China weakness is structural, not transient.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.